Armstrong Asia   of Singapore selected as NeuroSigma’s manufacturing partner Investment led by Checkmate Capital  as part of strategic partnership with Armstrong Asia First commercial units to be delivered in March 2026    LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) --   NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, today announced completion of an approximately $1 million investment into a high-volume manufacturing line for the second-generation Monarch exte

Company dispensed over 1,000 FDA-cleared systems in pilot phase; unveils new website and second-generation device for early 2026 launch LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, today announced the successful completion of its pilot commercialization program for the first-generation Monarch eTNS ®  System and the launch of a new website in preparation for release of its second-generation Monarch device. The

Peer-reviewed results of PET neuroimaging demonstrate rapid and profound changes to humans receiving eTNS LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, today announced a new publication in the journal Neuromodulation: Technology at the Neural Interface.  The publication, titled "Oxygen-15 Labeled Positron Emission Tomography During External Trigeminal Nerve Stimulation ," is the first-ever to report the real-tim

THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced...

SINGAPORE, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Armstrong Asia, a leading Singapore-based manufacturer of flexible material solutions with...

Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer...

LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company commercializing the Monarch...

Trial to be conducted at UCLA and funded by a grant from National Institute on Alcohol Abuse and Alcoholism (NIAAA) First phase of trial...